“Important issues related to the progress of vaccine development, regulatory approvals and acquisitions were discussed,” the prime minister tweeted.
Various issues were reviewed, such as prioritizing population groups, communication with health workers, cold chain infrastructure and… https://t.co/O4Kd6XAXyl
– Narendra Modi (@narendramodi) 1605887514000
The PM reviewed the aspects of the authorization of emergency use and the manufacture and acquisition of medicines. As Phase 3 trial results arrive, regulators will quickly review them to obtain the appropriate use authorization. Adar Poonawala from the Serum Institute, which makes the vaccine in India, has indicated that he may approach the Indian regulator shortly after the UK partner reveals the results of the phase 3 trial. This means that the first vaccines may be available for priority health worker beneficiaries in India in January.
A press release said the vaccine supply chain was being improved and non-vaccine supplies were increasing. Medicine and nursing students and professors will participate in the training and implementation of the program. The government has provided a grant of Rs 900 crore to support vaccine research and development.
.
